Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus

Celsion Corp.CLSN provided an update on its GEN 1 immunotherapy pipeline. The company said that the first cohort of patients in the phase Ib dose escalating study (OVATION) on GEN 1 plus the standard of care has been completed.